Kadmon Corporation was an American biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for rare and serious diseases.
History
- Founded in 2009 as Kadmon Holdings, Inc., the company was headquartered in South San Francisco, California.
- In 2020, Kadmon completed a merger with a special‑purpose acquisition company (SPAC), resulting in its public listing on the Nasdaq Global Market under the ticker symbol KDMN and the adoption of the name Kadmon Corporation.
- In January 2021, French multinational pharmaceutical company Sanofi announced the acquisition of Kadmon Corporation for approximately $1.9 billion, a transaction that was completed later that year.
Business Focus
Kadmon’s pipeline centered on therapies targeting rare genetic and metabolic disorders, as well as immune‑mediated diseases. The company pursued both internal drug discovery programs and strategic collaborations with academic and industry partners.
Key Products and Programs
- KRN23 (burosumab): An anti‑FGF23 monoclonal antibody for the treatment of X‑linked hypophosphatemia (XLH). (Note: While burosumab was originally developed by a different entity, Kadmon held development rights for certain indications.)
- KDM001: An oral small‑molecule inhibitor investigated for the treatment of autoimmune and inflammatory conditions.
- Additional preclinical and early‑stage candidates targeting metabolic and neurodegenerative diseases were under investigation.
Acquisition by Sanofi
Sanofi’s acquisition was motivated by Kadmon’s pipeline of rare‑disease therapeutics, which aligned with Sanofi’s strategic emphasis on specialty medicines. Post‑acquisition, Kadmon’s programs were integrated into Sanofi’s specialty care business unit.
Corporate Status
Following the acquisition, Kadmon Corporation ceased to operate as an independent public entity and its assets became part of Sanofi’s internal structure.
References
- Sanofi press release, “Sanofi completes acquisition of Kadmon Corporation,” February 2021.
- Nasdaq filing, “Kadmon Corporation – Form 8‑K,” March 2020.
Note: The information provided reflects publicly available and verifiable sources up to the knowledge cutoff date of September 2021.